Several preclinical studies that used OPG systemically for treatment of bone disorders have revealed that OPG inhibits bone resorption and improves osteoblastogenesis and new bone formation (Yao et al., 2011; Jin et al., 2007; Lamoureux et al., 2007). The gene discussed is TNFRSF11B; the disease is bone disorder.